Loading market dashboard
10x Genomics, Inc.
TXGHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics, a leader in single cell and spatial genomics tools, reported a notable insider sale amid ongoing sector innovation.
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10x Genomics provides advanced tools for single cell and spatial biology research, serving academic and biopharma institutions worldwide.
Torex Gold Resources Inc. (TXG:CA) Q1 2026 Earnings Call Transcript
10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.
TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
10x Genomics (TXG) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.36 per share a year ago.
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLEASANTON, Calif., April 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, at 5:00 p.m.
SAN CARLOS, Calif.--(BUSINESS WIRE)--LiquidCell Dx, a precision diagnostics company building a blood-based platform for tumor microenvironment profiling, today announced the appointment of Mirna Jarosz as Chief Executive Officer and Vincent A. Miller, MD, as Senior Strategic Advisor. The appointments add operating, commercialization and clinical leadership as the company advances its platform and prepares for the next stage of growth. Comprehensive genomic profiling changed oncology by making t.
TXG stock jumps after unveiling Atera, a next-gen spatial biology platform aiming to scale single-cell analysis and deepen its role in drug discovery and research.
Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale Debuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the Perelman School of Medicine, University of Pennsylvania and German Cancer Research Institute (DKFZ) PLEASANTON, Calif., April 18, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced Atera, a new in situ spatial biology platform engineered to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale.
Hinge Health (NYSE: HNGE - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations. Profitability This table compares Hinge Health and
PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2026 after market close on Thursday, May 7, 2026.
10x Genomics (NASDAQ: TXG - Get Free Report) and HeartSciences (NASDAQ: HSCS - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation. Institutional and Insider Ownership 84.7% of 10x Genomics shares
Aaron Wealth Advisors LLC raised its holdings in 10x Genomics (NASDAQ: TXG) by 68.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,414 shares of the company's stock after acquiring an additional 26,884 shares during the quarter. Aaron Wealth Advisors
Shares of 10x Genomics (NASDAQ: TXG - Get Free Report) gapped up prior to trading on Tuesday after William Blair upgraded the stock from a market perform rating to an outperform rating. The stock had previously closed at $19.81, but opened at $21.00. 10x Genomics shares last traded at $20.9670, with a volume of 150,356 shares
• 10x Genomics shares are powering higher. What's fueling TXG momentum?
10x Genomics (NASDAQ: TXG - Get Free Report) has earned a consensus recommendation of "Hold" from the sixteen ratings firms that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and four have issued a buy recommendation on the company. The
Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way for its stablecoin domain.
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today The Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal atlas, starting in oncology and immunology tissue, designed to generate harmonized multi-omics patient data. A Strategic Partnership with 10x Genomics: Leveraging the Xenium spatial transcriptomics platform as the foundational partner for the launch, the initiative sets a new benchmark for reproducible, AI-ready data generation across leading research institutions worldwide.
10x Genomics is undervalued, with a BUY rating and 18% upside to a $20.47 target, driven by robust consumables growth. Consumables, comprising 83% of revenue, continue double-digit growth, offsetting post-COVID instrument sales normalization and supporting recurring revenue expansion. TXG maintains a dominant 34% market share in single-cell biology, reinforced by increasing academic mindshare and strategic partnerships to drive future penetration.
Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's high makes it a compelling consideration.
10x Genomics (NASDAQ: TXG - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings. Profitability This table compares 10x
- Fueled by best-in-class technology and deep expertise in genome engineering and AI, PerturbAI is uniquely positioned to redefine therapeutic discovery, making it more scalable, translatable and cost-efficient - - Dataset of 8 million brain-wide cells, generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery engine - SAN FRANCISCO, March 17, 2026 /PRNewswire/ -- PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the public release of the world's largest in vivo CRISPR atlas. The 8 million-cell, brain-wide dataset represents the largest known causal genomics resource generated directly in living tissue.
On March 16, 2026, cooling oil prices meant markets erased some of last week's losses today, though geopolitical risks lingered.
Shares of Torex Gold Resources Inc. (TSE: TXG - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of C$63.34 and traded as high as C$76.96. Torex Gold Resources shares last traded at C$74.93, with a volume of 609,568 shares traded. Analyst Upgrades and
10x Genomics (NASDAQ: TXG - Get Free Report) and MSP Recovery (NASDAQ: MSPR - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk. Risk and Volatility 10x Genomics has a beta
